Syndax Pharmaceuticals (SNDX) R&D Day 2026 summary

Pipeline overview and program updates

• Deep and expanding pipeline includes Revuforj (revumenib), Niktimvo (axatilimab), SNDX-4321 (allosteric EGFR inhibitor), and SNDX-62122 (next-gen menin inhibitor), targeting acute leukemia, GVHD, IPF, myelofibrosis, and EGFR-mutant NSCLC.

• Four innovative assets expected in the clinic by 2027, with multiple near-term catalysts and blockbuster potential across oncology and fibrotic diseases.

• Revuforj and Niktimvo are established, with ongoing expansion into frontline and combination settings.

• SNDX-4321 and SNDX-62122 are advancing toward IND submissions and clinical trials, with SNDX-4321 IND targeted for year-end 2026 and SNDX-62122 for 2027.

• Multiple blockbuster opportunities identified across five therapeutic areas.

Clinical trial data and development milestones

• Revuforj pivotal registrational studies (EVOLVE-2, 7+3) are enrolling globally for newly diagnosed AML, with new data readouts expected in 2H26 and beyond.

• Proof-of-concept trial for menin inhibition in myelofibrosis with Revuforj to start in Q4 2026, with SNDX-62122 IND and Phase 1 in 2027 and initial data anticipated in 2H27.

• Niktimvo is in two major frontline GVHD trials, with key readouts expected in the coming year and additional Phase 2/3 data in 4Q26 and early 2028.

• MAXPIRe phase II trial for axatilimab in IPF completed enrollment; top-line data expected Q4 2026.

• SNDX-4321 IND filing targeted for year-end 2026, with Phase 1 in NSCLC planned for 2027 and initial data early 2028.

R&D strategy and innovation priorities

• Focus on translating early science into rapid clinical proof-of-concept, leveraging internal and external collaborations and strong scientific partnerships.

• Prioritization of first- and best-in-class assets, with emphasis on disease-modifying potential and combination strategies.

• Deep expertise in menin and CSF1R inhibition, and expansion into EGFR-mutant lung cancer.

• Integrated evidence generation plan and next-gen inhibitor library to maintain leadership in menin inhibition.

• Pipeline expansion driven by in-license and internal development strategies targeting high unmet needs.